PNLIP and obesity disorder: Tetrahydrolipstatin (orlistat), a derivative of the naturally occurring lipase inhibitor lipstatin from Streptomyces toxytricini, has been approved for the treatment of obesity due to its potent inhibition of pancreatic lipases [21], [22].